Press releases appear below, filter by date.
Lundbeck Limited, A Menarini Pharma, Bayer plc, HRA Pharma UK and GlaxoSmithKline have each breached Clause 2 of the ABPI Code of Practice and are the subject of advertisements in the medical, pharmaceutical and nursing press.
2014 Interactive Code launched. Updated guidance and advice documents published. Transfer of Value Disclosure Crib Notes published
Allergan Limited, Shire Pharmaceuticals Limited, Gedeon Richter and Sanofi have breached the ABPI Code of Practice for the Pharmaceutical Industry.
Comments are invited on proposals to amend Clause 16.3 with regards to representatives examinations.
The amendments result from the new EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations and changes to the EFPIA Code on the Promotion of Prescription-Only Medicines to, and Interactions with, Healthcare Professionals. Other amendments to the ABPI Code and the PMCPA Constitution and Procedure were also agreed.
Gedeon Richter (UK) Ltd has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Shire Pharmaceuticals Ltd and Roche Products Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
The amended text is available on the PMCPA website
Chiesi Ltd and Vifor Pharma UK Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, Chiesi was publicly reprimanded.
Proposals to amend the ABPI Code of Practice for the Pharmaceutical Industry were agreed at an Extraordinary General Meeting of the ABPI on Monday 11 June.
Bayer HealthCare has breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press.
Merz Pharma, Lilly and Daiichi-Sankyo have each breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.
